Business
OXB Appoints Non-Executive Director
OXB Appoints Non-Executive Director.
About this update from Oxford Biomedica Plc
[{"type":"text","content":"\n\n \nOxford Biomedica Appoints Laurence Espinasse as Non-Executive Director\n \n \nOxford, UK - 25 July 2024: Oxford Biomedica plc (LSE:OXB) (\"Oxford Biomedica\", \"OXB\" or \"the Company\"), a quality and innovation-led cell and gene therapy CDMO, today announces the appointment of Laurence Espinasse as a Non-Executive Director, effective as of 24 July 2024.\n \nMs. Espinasse brings more than two decades of experience across the legal and healthcare sectors and since 2021 has served as the General Counsel and Compliance Officer at Institut Mérieux SA (\"Institut Mérieux\"). Following the acquisition of ABL Europe (since renamed Oxford Biomedica (France)) in January 2024, Institut Mérieux is now a major shareholder in Oxford Biomedica, owning more than 10 percent of the Company's ordinary shares.\n \nPrior to her current role at Institut Mérieux, Ms. Espinasse was a Partner and Head of the Business Law Department at MDL Société d'Avocats. Before that, she practiced business law at EY. She obtained her professional lawyer's certificate from the École des Avocats Centre Sud in Montpellier, France.\n \nDr. Roch Doliveux, Chair of Oxford Biomedica, commented: \"On behalf of the Board, I am delighted to welcome Laurence Espinasse as Non-Executive Director. Her vast legal experience will be a strong asset for the Company as we look to build on significant commercial momentum and capitalise on the fast-growing cell and gene therapy sector. We look forward to her support and advice in driving OXB's continued success.\"\nLaurence Espinasse, incoming Board Member at Oxford Biomedica, added: \"Following the acquisition of ABL Europe, I am honoured to be joining Oxford Biomedica's Board of Directors. Institut Mérieux's significant investment reflects our confidence in Oxford Biomedica's potential. I look forward to working closely with the Board to drive the next phase of growth as a world-leading cell and gene therapy CDMO.\"\nRelevant disclosures\n \nMs. Espinasse previously served as a director at Transgene SA, from May 2022 to May 2023. There are no additional disclosures required to be made in accordance with LR 9.6.13R.\n-Ends-\n \nEnquiries: \nOxford Biomedica plc:\nSophia Bolhassan, Head of Investor Relations - T: +44 (0) 1865 509 737 / E: [email protected]\nICR Consilium:\nT: ...